GlassScriptPhysician profile
Sulagna De
NPI 1568515161
$7,480.59
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,870 · 2020: $1,436 · 2021: $1,609 · 2022: $1,401 · 2023: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,548.00 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,004.88 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $923.38 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $678.70 | 2019-2023 | Tradjenta, Jardiance, Trijardy Xr |
| Astrazeneca Pharmaceuticals LP | $585.54 | 2019-2023 | Farxiga |
| Amgen INC. | $456.54 | 2019-2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $390.55 | 2019-2021 | |
| Pfizer INC. | $279.46 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $264.82 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $177.25 | 2021 | |
| Alkermes, INC. | $124.65 | 2019-2020 | |
| Allergan, INC. | $108.64 | 2019-2020 | |
| Abbott Laboratories | $105.17 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $105.15 | 2021-2023 | Vraylar |
| Biohaven Pharmaceutical Holding Company LTD. | $104.87 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $63.31 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $60.23 | 2022-2023 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $58.55 | 2019-2020 | |
| Esperion Therapeutics, INC. | $58.05 | 2022 | |
| Hikma Pharmaceuticals USA | $53.64 | 2021-2022 | |
| Bausch Health US, LLC | $45.12 | 2020-2021 | |
| Exact Sciences Corporation | $42.75 | 2023 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $32.22 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $26.75 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $26.38 | 2019 | |
| Melinta Therapeutics, LLC | $21.67 | 2019 | |
| Astellas Pharma US INC | $20.40 | 2021 | |
| Philips North America LLC | $19.69 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $18.05 | 2021 | |
| Orexo US, INC. | $17.08 | 2019 | |
| Aytu Biopharma, INC. | $16.79 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.33 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.05 | 2023 | Quviviq |
| Amarin Pharma, INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sulagna De listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.